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Abstract
Aims/hypothesis Pancreatic lymph nodes (PLNs) are critical
sites for the initial interaction between islet autoantigens and
autoreactive lymphocytes, but the histology of PLNs in tissue
from individuals with type 1 diabetes has not been analysed in
detail. The aim of this study was to examine PLN tissue sections
from healthy donors compared with those at risk of, or with
recent-onset and longer-duration type 1 diabetes.
Methods Immunofluorescence staining was used to examine
PLN sections from the following donor groups: non-diabetic
(n=15), non-diabetic islet autoantibody-positive (n=5), recent-
onset (≤1.5 years duration) type 1 diabetes (n=13), and longer-
duration type 1 diabetes (n=15). Staining for CD3, CD20 and
Ki67 was used to detect primary and secondary (germinal
centre-containing) follicles and CD21 and CD35 to detect
follicular dendritic cell networks.
Results The frequency of secondary follicles was lower in the
recent-onset type 1 diabetes group compared with the non-
diabetic control group. The presence of insulitis (as evidence
of ongoing beta cell destruction) and diagnosis of type 1 diabe-
tes at a younger age, however, did not appear to be associated
with a lower frequency of secondary follicles. A higher
proportion of primary B cell follicles were observed to lack
follicular dendritic cell networks in the recent-onset type 1 dia-
betes group.
Conclusions/interpretation Histological analysis of rare
PLNs from individuals with type 1 diabetes suggests a previ-
ously unrecognised phenotype comprising decreased primary
B cell follicle frequency and fewer follicular dendritic cell
networks in recent-onset type 1 diabetes.
Keywords Histology . Islet autoimmunity . Pancreatic lymph
nodes . Type 1 diabetes
Abbreviations
FDC Follicular dendritic cell
FFPE Formalin-fixed, paraffin-embedded
GADA GAD autoantibody
IA-2A Islet antigen-2 autoantibody
LT Lymphotoxin
nPOD Network for Pancreatic Organ Donors with Diabetes
pc Corrected p value
PLN Pancreatic lymph node
Tfh T follicular helper
TNF Tumour necrosis factor
uMinn University of Minnesota (cohort)
ZnT8A Zinc transporter 8 autoantibody
Introduction
Type 1 diabetes develops as a result of the immune-mediated
destruction of insulin-secreting beta cells in the islets of
Langerhans of the pancreas. Although the aetiology of the
disease is not fully understood, it is underpinned by a
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combination of well-established genetic factors and as-yet un-
identified environmental factor(s) [1–3].
Evidence of insulitis has been reported in histological
pancreas specimens from donors with recent-onset type 1
diabetes, along with a marked reduction in islets that stain
positively for insulin compared with specimens from healthy
controls [4–6]. The immune infiltrate consists mainly of CD8+
cytotoxic T cells, CD20+ B lymphocytes and, to a lesser
extent, CD4+ T cells, monocytes and natural killer cells [7].
Islet beta cells are the target of immune-mediated attack but it
is within secondary lymphoid organs that lymphocytes are
primed with their cognate antigen to initiate humoral and
T cell responses [8, 9].
In humans, several pancreatic lymph nodes (PLNs; the num-
ber differs among individuals but can be >50) are located at the
periphery of the pancreas [10]. Lymph nodes are highly
organised structures that are densely populated with supportive
stromal cells, antigen-presenting dendritic cells, macrophages
and migrating lymphocytes. The lymph node environment con-
tinually evolves in response to foreign pathogens and, in the
case of autoimmunity, self-antigens. Human lymph nodes con-
sist of an outer capsule; a cortex of B cell follicles (outer zone)
and T cells (inner zone); the medulla, through which medullary
sinuses branch, facilitating the migration of cells; and the hilum,
through which the lymph fluid exits the lymph node to flow
through lymphatic vessels that connect each of the lymph nodes.
Within lymph nodes, B cell follicles exist in two major
stages: primary and secondary. Primary follicles are populated
by naive, mature follicular B cells and marginal zone B cells.
Secondary B cell follicles are defined by the presence of ger-
minal centres, which form when B cells encounter their cog-
nate antigen. Upon antigen recognition, B cells migrate to the
outer T cell zone, where they undergo cognate interactions
with Tcells before initiating the formation of germinal centres.
Then, they rapidly proliferate and undergo class-switching,
somatic hypermutation and affinity maturation to generate B
cell clones of the highest affinity and specificity for their cog-
nate antigen [11, 12]. Follicular helper T cells participate in B
cell selection within the germinal centre light zone [13].
Germinal centres are important for the generation of memory
B cells and long-lived antibody-producing plasma cells.
Follicular B cells and specialised stromal cells, known as fol-
licular dendritic cells (FDCs), are co-dependent. A positive
feedback loop exists in which FDCs secrete the chemokine,
CXCL13, which recruits CXCR5-expressing B cells, causing
them to aggregate into follicular structures. CXCL13 stimu-
lates the secretion from follicular B cells of tumour necrosis
factor (TNF) and lymphotoxin (LT), which are essential for
FDC development and maintenance [14–16].
Most reported studies of PLNs in type 1 diabetes disrupt the
PLN structure to isolate the resident cells [17–19]. Histological
studies of PLNs from human donors with type 1 diabetes are
therefore rare. In particular, there are practically no studies of
the PLN during the very early stages of disease when insulitis
and residual beta cells are prevalent because of the rarity of
human PLN tissues for research purposes. The aim of this
study was to gain new insights into the immunological and
architectural components of human PLNs, both preceding
and during recent-onset and longer-duration type 1 diabetes.
Methods
Pancreatic lymph node tissues Human PLN tissue sections,
representing all currently available resources, were obtained
from the National Health Service Research Scotland Greater
Glasgow and Clyde Biorepository (hereafter referred to as the
UK cohort), the JDRF Network for Pancreatic Organ Donors
with Diabetes (nPOD) programme (the nPOD cohort) and the
University of Minnesota (the UMinn cohort), with kind
permission from B. Hering, Division of Diabetes,
Endocrinology and Metabolism, University of Minnesota,
Minneapolis, USA. UK cohort specimens were archival, for-
malin-fixed, paraffin-embedded (FFPE) tissues, details of
which have been published previously [4, 5, 20–22]. This
study used nPOD-assigned nomenclature for each donor
obtained from the nPOD cohort. PLNs from the nPOD cohort
were provided as either snap-frozen or FFPE sections,
depending on availability. PLN specimens from the UMinn
cohort were provided as snap-frozen sections. Details of all
donors are listed in Table 1 and Fig. 1. Tissues from each
source were provided as 4–8 μm sections mounted on glass
microscopy slides. To increase the statistical power, PLN sam-
ples from each cohort were analysed together. The demographics
of the groups were: non-diabetic control donors (n=15; six men,
eight women), age range 2–31 years (mean ± SD 16.3 ±
2.7 years); autoantibody-positive donors (n=5; three men, two
women), age range 22–69 years (mean±SD 38.3±8.5 years);
recent-onset type 1 diabetic donors (n=13; sixmen, sevenwom-
en), age range 5–27 years (mean±SD 16.2±2.0 years), duration
of type 1 diabetes 0.02–1.50 years; and longer-duration type 1
diabetic donors (n=15; nine men, six women), age range 11–
34 years (mean±SD 21.4±1.7 years), duration of type 1 diabe-
tes 4–19 years (mean±SD 7.8±1.2 years, median 6.0 years).
Islet autoantibody data (micro-insulin autoantibody [mIAA],
IA-2A, GADA, ZnT8A) were available for nPOD participants
only. These data are included in Table 1 but were not analysed
because most samples were tested years after diagnosis. In addi-
tion, autoantibodies to insulin cannot be discriminated from an-
tibodies to therapeutic insulin. This study was carried out with
ethical approval from NRES Midlands-Edgbaston Research
Ethics Committee (13/WM/0300).
Dual antibody immunofluorescence staining To prepare
FFPE tissues for labelling, sections were de-waxed with xylene
and rehydrated through a decreasing ethanol series into distilled
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H2O. Heat-induced epitope retrieval was used to unmask
antibody-binding epitopes as follows: sections were enclosed
in a microwavable container containing 10 mmol/l Tris and
1 mmol/l EDTA (pH 9.0), and heated on full power (800 W)
for 20 min, followed by 20 min cooling at room temperature.
To prepare fresh-frozen tissues for labelling, sections were air-
dried and immediately incubated with ice cold 10% formalin
for 15 min, followed by three 5 min PBS (pH 7.4) washes. At
this stage, frozen and FFPE sections were processed identically.
Non-specific binding sites were blocked with 0.1% BSA in
PBS supplemented with 5% normal goat serum for 30 min
prior to incubation with primary antibody. Primary antibody
binding was detected with fluorochrome-conjugated secondary
antibodies specific to IgG of the primary antibody host species.
Sections were mounted under glass coverslips with ProLong
Gold Antifade mounting medium containing DAPI (Life
Technologies). Details of all primary and secondary antibodies
are shown in Table 2.
Table 1 Details of donors of PLN tissue included in the study
Donor code Cohort Participant type Age (years) Sex (M/F) T1D duration
(years)
Autoantibodies Insulitis in
pancreas (Y/N)
FD1 UK RO T1D 12 F 0.2 ND Y
FD2 UK RO T1D 11 F Recent ND Y
FD3 UK RO T1D 15 M 0.5 ND Y
FD4 UK RO T1D 5 M Recent ND Y
FD5 UK RO T1D 14 F Recent ND Y
FD6 UK RO T1D 22 F Recent ND N
FD7 UK RO T1D 7 F <1 week ND Y
FD8 UK RO T1D 27 F Recent ND Y
FD9 UK LD T1D 20 M 6 ND N
FC1 UK Control 2 F N/A ND N
FC2 UK Control 18 F N/A ND N
6052 nPOD RO T1D 12 M 1 IA-2A, mIAA Y
6070 nPOD LD T1D 25.8 F 7 IA-2A, mIAA Y
6076 nPOD LD T1D 24 M 14 GADA, mIAA Y
6087 nPOD LD T1D 17.5 M 4 mIAA, ZnT8A Y
6088 nPOD LD T1D 31.2 M 5 GADA, IA-2A, mIAA Y
6121 nPOD LD T1D 33.9 F 4 Negative N
6195 nPOD LD T1D 19.2 M 5 GADA, IA-2A, mIAA, ZnT8A Y
6211 nPOD LD T1D 24 F 4 GADA, IA-2A, mIAA N
6212 nPOD LD T1D 20 M 5 mIAA Y
6224 nPOD RO T1D 21 F 1.5 Negative Y
6228 nPOD RO T1D 13 M 0 GADA, IA-2A, ZnT8A Y
6243 nPOD LD T1D 13 M 5 mIAA Y
6245 nPOD LD T1D 22 M 7 GADA, IA-2A Y
6247 nPOD RO T1D 24 M 0.6 mIAA Y
6264 nPOD LD T1D 12 F 9 Negative Y
6265 nPOD LD T1D 11 M 8 GADA mIAA Y
6080 nPOD AutoAb+ 69.2 F N/A GADA, mIAA N
6158 nPOD AutoAb+ 40.3 M N/A GADA, mIAA N
6167 nPOD AutoAb+ 37 M N/A IA-2A, ZnT8A N
6197 nPOD AutoAb+ 22 M N/A GADA, IA-2A Y
6267 nPOD AutoAb+ 23 F N/A GADA, IA-2A Y
6024 nPOD Control 21 M N/A Negative N
6094 nPOD Control 2.9 M N/A Negative N
6098 nPOD Control 17.8 M N/A Negative N
6137 nPOD Control 8.9 F N/A Negative N
6179 nPOD Control 21.8 F N/A Negative N
6182 nPOD Control 2 M N/A Negative N
6229 nPOD Control 31 F N/A Negative N
6233 nPOD Control 14 M N/A Negative N
6235 nPOD Control 31 M N/A Negative N
6234 nPOD Control 20 F N/A Negative N
6238 nPOD Control 20 M N/A Negative N
MD1 UMinn LD T1D 23 F 19 ND ND
MD2 UMinn LD T1D 24 F 15 ND ND
MD3 UMinn RO T1D 27 M 1.5 ND Y
MC1 UMinn Control ND F N/A ND ND
MC2 UMinn Control ND F N/A ND ND
AutoAb+ , autoantibody-positive, non-diabetic; F, female; M, male; mIAA, micro-insulin autoantibody; N, no; N/A, not applicable; ND, not determined;
Neg, negative; LD T1D, longer-duration type 1 diabetes; RO T1D, recent-onset type 1 diabetes; Y, yes
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Triple antibody immunofluorescence stainingUse of a triple
immunostaining system enabled two primary antibodies raised
in the same species to label the same section without cross-
reactivity [23, 24]. In this system, sections were processed as
described above until the blocking stage and then incubated with
rabbit anti-CD3 primary antibody. A goat anti-rabbit Alexa Fluor
594 TSA (‘tyramide signal amplification’) kit (ThermoFisher
Scientific, Waltham, MA, USA) following the manufacturer’s
instructions was used to detect and amplify the signal. After
stringent PBS washes, sections were incubated with a cocktail
of mouse anti-CD20 and rabbit anti-Ki67 primary antibodies,
which were detected with goat anti-mouse Alexa Fluor 488
(ThermoFisher Scientific) and goat anti-rabbit DyLight 405
(ThermoFisher Scientific) secondary antibodies, respectively.
Sections were mounted with ProLong Gold Antifade mounting
medium without DAPI.
Image capture and analysisThe area of each PLN sectionwas
measured using a Leica AF 6000 microscope fitted with a Leica
DFC365FX 8/12 bit monochrome camera in combination with
LASX software (Leica Microsystems, Milton Keynes, UK). An
automated stage was used in combination with the software’s
automatic tiling function to capture complete images of the
whole sections. B cell follicles and germinal centres were ob-
served and quantified based on detection of ≥3 CD20+ Ki67+
cells within a B cell follicle and characteristic histological fea-
tures. The total number of B cell follicles/mm2 of PLN and the
percentage of follicles that had formed germinal centres (second-
ary follicles) were quantified. T cell and B cell zones were dis-
tinguished by the presence of CD3+ and CD20+ cells, respec-
tively. FDCs were identified as CD21+ CD35+ cells. Each B cell
follicle was designated as either positive or negative for an FDC
network following examination of adjacent sections.
Statistical analysis A Kruskal–Wallis H nonparametric test of
independent samples was used to compare the number of folli-
cles/mm2, the percentage of follicles with germinal centres and
the percentage of follicles positive for FDCs among donor groups
using IBM SPSS Statistics software (version 21, Chicago, IL,
USA). A p value of <0.05was considered statistically significant.
The number of follicles with germinal centres was compared in
PLNs fromdonorswith recent-onset and longer-duration diabetes
and controls. The insulitis score and age at onset were included as
indicators of disease severity. Bonferroni correction was included
to correct for multiple comparisons. Corrected (pc) and uncor-
rected (p) probability values are presented.
Results
Secondary follicles in PLNs from recent-onset type 1
diabetic donors Secondary B cell follicles, as indicated by
germinal centre formation, were quantified in PLN tissue sections
stained for CD3 (Tcells), CD20 (B cells) and Ki67 (proliferating
Non-diabetic
n=15
nPOD
n=11
UK cohort
n=2
AAb
+
 n=5
nPOD
W/insulitis
n=2
Recent-onset T1D
(≤1.5y) n=13
nPOD
n=4
UK cohort
n=8
Longer-duration T1D
(>1.5y) n=15
nPOD
n=12
UK cohort
n=1 
W/insulitis
n=4
W/insulitis
n=10 
W/insulitis
n=7
W/insulitis
n=1 
UMinn
n=2
UMinn
n=1
UMinn
n=2
W/insulitis
n=1
W/insulitis
n=ND 
Fig. 1 Flow diagrams detailing the number of donors with and without insulitis from the three cohorts utilised for the study. T1D, type 1 diabetes;
W/insulitis, presence of insulitis
Table 2 List of antibodies used
in the study Antigen Species Clone Conjugate Manufacturer Dilution
CD3 Rabbit Polyclonal Unconjugated Dako 1/100
CD20 Mouse L26 Unconjugated Dako 1/200
Ki67 Rabbit SP6 Unconjugated Abcam 1/100
CD21 Mouse 2G9 Unconjugated AbD Serotec 1/50
CD35 Rabbit EPR6602 Unconjugated Abcam 1/400
Rabbit IgG (H&L) Goat – HRP Life Technologies 1/200
Rabbit IgG (H&L) Goat – DyLight 405 Vector Laboratories 1/100
Mouse IgG (H&L) Goat – Alexa Fluor 488 Life Technologies 1/200
Rabbit IgG (H&L) Goat – Texas Red Vector Laboratories 1/100
H&L, heavy and light chains; HRP, horseradish peroxidase
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cells; Fig. 2). Control PLNs displayed a well-organised structure,
with distinct differential B and T cell localisation and clearly
defined follicles. The cellular organisation of PLNs from each
recent-onset type 1 diabetic donor was altered compared with
those from non-diabetic controls and longer-duration type 1 dia-
betic donors: primary follicles had less distinct, more diffuse
structures, with poor differential localisation of the B cell and T
cell subsets. This disorganised phenotype was also observed in
islet autoantibody-positive PLNs.
For primary and secondary follicle analysis, PLNs were
analysed by duration of diabetes (recent onset ≤1.5 years
duration, longer duration >1.5 years duration). The total area
of PLN tissue varied in non-diabetic controls (n=15) and
autoantibody-positive (n=5), recent-onset type 1 diabetes
(n=13) and longer-duration type 1 diabetes (n=15) donors
(p=0.005), but the mean frequency of total B cell follicles per
mm2 of PLN did not differ among groups (p=0.43; Table 3).
Overall, the frequency of total B cell follicles containing a
germinal centre was lower in PLNs from recent-onset type 1
diabetic donors compared with controls (5.0±2.1% [median
0.0%] vs 21.9±5.6% [median 14.3%], respectively, p=0.003,
pc=0.009; Table 4 and Fig. 3a), while longer-duration type 1
diabetic donors were not different from controls (10.9±3.8%
[median 8.6%] p=0.21). Germinal centre frequency was not
significantly different in islet autoantibody-positive donors
(6.7 ± 2.1% [median 7.8], p=0.055, pc=0.165) compared
with controls.
Secondary follicles in PLNs from type 1 diabetic donors
with insulitis Next, tissues were stratified by the presence or
absence of insulitis in the pancreas, irrespective of disease
duration. Data regarding evidence of insulitis was ascertained
from previous studies involving the same donors, and from
nPOD online pathology information [5, 22, 25]. The insulitis
status of two of the type 1 diabetic donors could not be
established (MD1, MD2) and were not therefore included in
this part of the analysis. There was a reduction in the frequency
of secondary follicles in PLNs from type 1 diabetic donors with
insulitis (n=22) compared with non-diabetic controls (9.2
± 2.7% [median 7.7%] vs 21.9 ± 5.6% [median 14.3%],
p= 0.014; pc= 0.042; Fig. 3b). Only four type 1 diabetic
donors without insulitis were included; this was considered
insufficient for analysis.
Secondary follicles in PLNs from recent-onset donors with
insulitis stratified for duration of diabetes Type 1 diabetic
donors were stratified by both duration of diabetes and evidence
of insulitis; those with evidence of insulitis were subdivided into
recent-onset (n=12) and longer-duration (n=10) groups. The
mean frequency of total follicles (n/mm2) was not significantly
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Fig. 2 Representative examples
of PLN B cell follicles images
showing CD20+ follicles (green),
Ki67 staining (blue), CD3+ Tcells
(red) and three-colour merged
labelling from non-diabetic
controls; autoantibody-positive
(AAb-pos), recent-onset type 1
diabetes (T1D; primary follicle)
donors; recent-onset T1D
(secondary follicle) donors; and
longer-duration T1D donors.
Scale bars, 50 μm
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different in the recent-onset type 1 diabetes with insulitis or
longer-duration type 1 diabetes with insulitis groups compared
with controls (2.1±0.4/mm2 [median 1.62/mm2], 2.0±0.3/mm2
[median 1.7/mm2] and 1.8±0.2/mm2 [median 1.8/mm2], respec-
tively; p=0.8). A reduction in the mean frequency of secondary
follicles was observed in recent-onset donors with insulitis com-
paredwithnon-diabeticdonors(n=15;5.4±2.0%[median0.0%]
vs 21.9±5.6% [median 14.3%], p=0.005, pc=0.015) but not in
longer-duration donorswith insulitis comparedwith non-diabetic
donors (13.8±5.0% [median 10.3%] vs 21.9±5.6% [median
14.3%], p=0.24; Fig. 3c).
Secondary follicles in PLNs from type 1 diabetic donors
diagnosed before the age of 15 years In the longer-duration
diabetes group, the time between diagnosis of type 1 diabetes
and death varied from 4 to 19 years. Considering the observed
difference in secondary follicle frequency in PLNs from do-
nors with recent-onset and longer-duration diabetes, the
phenotype of PLNs from the donors with longer-duration di-
abetes at the time of retrieval was unlikely to reflect the phe-
notype at diagnosis. Therefore, when examining the effect of
age at diagnosis of diabetes on the frequency of secondary
follicles, it was necessary to further analyse the recent-onset
type 1 diabetic donors (n=13; seven aged <15 years, six aged
≥15 years) in isolation because the length of time between
diagnosis of type 1 diabetes and death was very short
(≤1.5 years) and thus more likely to accurately reflect the
phenotype at diagnosis. There was no difference in secondary
follicle frequency between recent-onset type 1 diabetic donors
diagnosed at age <15 years and recent-onset type 1 diabetic
donors diagnosed at age ≥15 years (p=0.84; Fig. 3d), suggest-
ing that diagnosis at a younger age had no effect on the lower
frequency of secondary follicles in PLNs from donors with
recent-onset type 1 diabetes.
A proportion of primary follicles lack FDC networks in
donors with recent-onset type 1 diabetes PLN tissue sections
adjacent to those labelled for T cell, B cell and proliferating cell
markers (CD3, CD20 and Ki67, respectively) were stained for
the complement receptors CR1 (also known as CD35) and CD2
(also known as CD21). Both markers are highly expressed by
FDCs. Given their co-dependent relationship, FDC networks
were employed as another marker of B cell follicles. Absence
of FDC networks from a follicle was indicated by the lack of
CD21+ CD35+ immunopositive cells in regions of the outer
cortex that had CD20+ B cell follicles on an adjacent section
(Fig. 4a–d). Donors from the UMinn cohort were not included
in the FDC analysis because the sections were not always con-
secutive. In PLNs of the non-diabetic donor group, 98.1±1.3%
(median 100%; n=11) of follicles showed evidence of an FDC
network, compared with 94.9±3.6% (median 100%; n=5),
93.6±2.0% (median 94.75%; n=12) and 73.0±5.6% (median
75%; n=11; p=0.001; pc=0.003) of follicles in the autoanti-
body-positive, longer-duration type 1 diabetes and recent-onset
type 1 diabetic donor groups, respectively (Fig. 4e). Each donor
PLN containing one or more FDC-negative regions also
contained one or more FDC-positive regions. This finding sug-
gests that ineffective labelling of the CD21 and CD35 proteins
on certain donor tissues was not responsible for the lack of de-
tected FDCs within some follicles. Only subsets of primary fol-
licles were found to be FDC-negative, and all secondary follicles
contained CD21+ CD35+ cells.
Discussion
The aim of this study was to examine the phenotype of PLNs
from donors with varying duration of type 1 diabetes, includ-
ing islet autoantibody-positive, non-diabetic donors consid-
ered to have a high risk of future type 1 diabetes. A previously
unrecognised phenotype was revealed in PLNs from donors
Table 3 Details of the total and mean area of PLN examined per donor
group
Donor group PLN area (mm2)
Total Mean ± SEM
Non-diabetic control 192.6 12.84 ± 2.07
Autoantibody-positive 140.87 28.17 ± 9.64
Recent-onset T1D 70.1 5.39 ± 0.89
Longer-duration T1D 291.87 10.85 ± 3.8
T1D, type 1 diabetes
Table 4 Frequency of total B cells follicles and the percentage contain-
ing germinal centres
Donor group B cell follicle
frequency, per
mm2 (median)
Germinal centre
frequency, % of
total (median)
Non-diabetic controla 1.83 ± 0.22 (1.77) 21.91 ± 5.6 (14.3)
Autoantibody-positive 2.59 ± 0.42 (2.4) 6.66 ± 2.14 (7.84)
T1D
RO 1.99± 0.36 (1.55) 4.99 ± 2.1 (0.0)
LD 1.87± 0.28 (1.64) 10.85 ± 3.8 (8.64)
T1D with insulitis 9.22 ± 2.68 (7.7)
RO 2.1 ± 0.37 (1.62) 5.4 ± 2.2 (0.0)
LD 1.95± 0.34 (1.72) 13.78 ± 5.02 (10.32)
RO T1D
Dx <15 years 1.61 ± 0.39 (1.37) 5.56 ± 3.64 (0.0)
Dx ≥15 years 2.43 ± 0.63 (1.86) 4.35 ± 2.06 (2.94)
Data are means ± SEM
aNon-diabetic control group results remained consistent throughout the
analysis and are therefore described only once
Dx, diagnosis; LD, longer duration; RO, recent onset; T1D, type 1
diabetes
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with recent-onset type 1 diabetes, which was not observed in
PLNs from non-diabetic donors or those with a longer dura-
tion of diabetes. The recent-onset phenotype included a
disorganised structure and a reduced frequency of secondary
follicles, as well as a decreased frequency of follicles contain-
ing FDC networks. When the presence of insulitis was used
instead of time from onset, a reduced secondary follicle fre-
quency compared with controls was also observed. Diagnosis
of type 1 diabetes at a younger age did not appear to be asso-
ciated with lower germinal centre occurrence. In addition, the
follicle frequency in PLNs did not appear to be affected by
duration of diabetes or age at onset, suggesting that the lack of
secondary follicles could not be attributed to an overall reduc-
tion in, or an inability to form, primary follicles.
Previous histological studies of PLNs from donors with
type 1 diabetes are very limited. A recent study, however,
conducted a thorough examination of extracellular matrix pro-
teins in tissues from nPOD donors, and reported no difference
in germinal centre frequency in PLN tissue between donors
with and without type 1 diabetes [19]. Several differences in
study design between this former study and the current study
may explain the contradictory observations. In the former
study, donors with diabetes duration of up to 9 years were
grouped together as younger donors. In the present study,
donors with diabetes duration of ≤1.5 years were designated
the recent-onset diabetes group and all other type 1 diabetic
donors were designated the longer-duration diabetes group.
Comparison of the nPOD donors detailed in the former and
current studies showed that only four type 1 diabetic and two
control donors were utilised in both studies. The former study,
however, analysed multiple lymphoid tissues from the same
donors and did not identify which donors supplied the PLNs
studied. The labelling methods also differed in that CD3,
CD20 and Ki67 were co-stained in the present study, while
sequential sections were singly labelled for CD3 and CD20,
without the addition of a proliferation marker in the former
study. As rapid proliferation is the hallmark of a functional
germinal centre, the inclusion of Ki67 staining is a strength of
the current study. Another strength is the use of human tissue
samples from three cohorts of rare donors.
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Fig. 3 Plots demonstrating the percentage of total follicles in the second-
ary phase (per donor), as indicated by the presence of germinal centres
(GCs), in donors with and without type 1 diabetes (T1D). (a) Donors
stratified by duration of diabetes (recent-onset [RO] T1D n = 13, longer-
duration [LD] T1D n = 15). (b) Donors stratified by the presence
(w/insulitis) or absence (w/o insulitis) of pancreatic insulitis (T1D
w/insulitis n= 22, T1D w/o insulitis n = 4). (c) Donors stratified by both
T1D duration and the presence or absence of insulitis (RO T1D
w/insulitis, n = 12; LD T1D w/insulitis, n = 10; T1D w/o insulitis,
n= 4). (d) RO T1D donors diagnosed before age 15 years (<15 y, n= 7)
and at age 15 years or older (≥15 y, n = 6). Control donors, n = 15,
Autoantibody-positive (AAb-pos) donors, n= 5 for all plots. Each data
point represents a single donor. Donors with the same value are overlaid,
as indicated by a denser outline. *p < 0.05, **p < 0.01; †pc < 0.05,
††pc< 0.01. Dx, diagnosis
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Limitations of the study include the cross-sectional nature of
the investigation. This limitation cannot be addressed in human
studies because access to PLNs is largely restricted to post-
mortem retrieval. Sample size, particularly in stratified analy-
ses, was also a limitation but all PLNs available for study were
included. The labelling of only one PLN section per group of
markers limited the quantity of data that could be generated
from a single lymph node, but this could not be improved
because only a few sections were available per donor.
Another consideration was the use of both snap-frozen and
FFPE tissue sections, but low sample numbers necessitated
the use of both sample types. An in-house comparative analysis
showed that germinal centre identification was possible in both
snap-frozen and paraffin-embedded PLN tissue but, overall,
preservation of the tissue architecture was better in FFPE sec-
tions (data not shown). Therefore, FFPE sections were selected
where possible and snap-frozen tissues were chosen for staining
when FFPE tissue was unavailable. As the tissue samples were
from several different cohorts, consistent data on insulin-
containing islets in the adjacent pancreas were not available.
Insulitis scores may reflect insulin positivity but the pattern of
insulitis is known to be heterogeneous. This study also lacks a
functional analysis of PLN immune cells. However, such stud-
ies are being addressed by other groups [17, 18, 25], while the
current study sought to fill a gap in the knowledge of in situ
PLNs from relevant type 1 diabetic donors.
Research into the formation of primary and secondary folli-
cles is complex, involving cells and signalling proteins, and
therefore outside the scope of this observational study. Of par-
ticular importance are T follicular helper (Tfh) cells, a subset of
CD4+, CXCR5+ T cells that are integral to B cell affinity mat-
uration within germinal centres [26, 27]. T cells with a Tfh
phenotype were recently reported to be over-represented in
the blood of individuals with type 1 diabetes [28, 29].
Activated follicular B cells require intercellular CD40 (on B
cells), CD40L (on Tfh cells) co-stimulation to promote their
survival and affinity maturation [30, 31]. Although many stud-
ies have examined the mechanisms responsible for the forma-
tion and subsequent dissolution of germinal centres [32–34],
none to date have reported abrogation in germinal centre for-
mation in PLNs from mouse models of diabetes. Ptpn22
knockout (KO) mice, however, showed increased germinal
centre activity, which was attributed to increased proliferation
and survival of CD4+ Tfh cells [35]. If Ptpn22 KO and loss of
lymphoid protein tyrosine phosphatase (LYP) function results
in increased germinal centre activity, it could be argued that an
increase in LYP function could contribute to decreased germi-
nal centre activity. Another study showed that by disrupting the
lymphotoxin pathway during NOD mouse development, for-
mation of primary follicles and FDC networks in the spleen
was diminished but primary and secondary follicles formed
normally in the draining lymph nodes, including PLNs [36].
While acknowledging that this small observational study
requires future replication and mechanistic investigation, we
have considered possible explanations for the observation of
fewer secondary follicles with fewer germinal centres and
fewer FDC networks in PLNs from donors with recent-onset
diabetes. It is possible that reduced antigen presentation to B
cells or a breakdown in the normal process of secondary fol-
licle stimulation, with maturing autoreactive B cells being
pushed into antibody-producing plasma cells faster than usual,
could contribute to depletion of secondary follicles. It is not,
however, possible to address these possibilities histologically.
A potential role for B cells in the pathogenesis of type 1
diabetes is supported by a recent anti-CD20 trial [37] and by
the association of CD20+ B cell rich insulitis with rapid pro-
gression [38]. B cells may contribute to functional effects on
antigen presentation, co-stimulation or local cytokine secre-
tion and may therefore potentiate the autoreactive response in
type 1 diabetes.
e
Control
100
80
60
F
o
ll
ic
le
s
 w
it
h
 C
D
2
1
+
C
D
3
5
+
 F
D
C
s
 (
%
)
40
20
0
AAb-pos RO T1D LD T1D
††
**
a b
c d
Fig. 4 FDC networks in human PLNs. (a) Image shows two CD20+
primary B cell follicles (stained green, indicated by the white arrows in
all images) from a recent-onset type 1 diabetic donor. (b–d) Images
showing the same region in the section adjacent to the one shown in
(a), stained for (b) CD21 (green) and (c) CD35 (red) and (d) merged.
(d) The top left follicle contains CD21+ CD35+ FDCs (indicated by blue
arrows), which were not detected in the bottom follicle. Scale bar, 50 μm.
(e) The histogram shows the percentage of B cell follicles which
contained CD21+ CD35+ FDC networks in each donor group (control,
n = 15; Autoantibody-positive [Aab]-pos) donors, n = 5; recent-onset
[RO] T1D donors, n = 11; longer duration [LD] T1D, n = 12).
**p< 0.01; ††pc< 0.01
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In conclusion, we have described a histological observation
of diminished germinal centre activity close to diagnosis of
type 1 diabetes.
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